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Abstract
Folic acid contents of plasma, whole blood, liver and spleen in Rauscher leukemic mice were
estimated. Plasma and liver folate in the leukemic mice was lower than that of normal mice, sug-
gesting that folic acid was deficient in Rauscher leukemia. Folic acid contents in whole blood
and spleen were even higher in the leukemic mice than those in normal mice. Clearance study
by injecting folic acid intravenously into leukemic mice showed faster disappearance of folic
acid from the circulating blood, suggesting that folic acid demand of Rauscher leukemia is in-
creased. Methotrexate administered shortly after inoculation of the virus did not prevent Rauscher
leukemia. But anemia, reticulocytosis and erythroblastosis, which are commonly seen 3-4 weeks
later in leukemic controls, were not marked as compared with controls. It can be concluded that
the requirement of folic acid is greater in Rauscher leukemia than in controls, and methotrexate is
effective for preventing hematological changes commonly seen in this type of leukemias.
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Abstract: Folic acid contents of plasma, whole blood, liver and
spleen in Rauscher leukemic mice were estimated. Plasma and liver
folate in the leukemic mice was lower than that of normal mice, sug-
gesting that folic acid was deficient in Rauscher leukemia. Folic acid
contents in whole blood and spleen were even higher in the leukemic
mice than those in normal mice. Clearance study by injecting folic
acid intravenously into leukemic mice showed faster disappearance of
folic acid from the circulating blood, suggesting that folic acid demand
of Rauscher leukemia is increased. Methotrexate administered shortly
after inoculation of the virus did not prevent Rauscher leukemia. But
anemia, reticulocytosis and erythroblastosis, which are commonly seen
3-4 weeks later in leukemic controls, were not marked as compared
with controls. It can be concluded that the requirement of folic acid
is greater in Rauscher leukemia than in controls, and methotrexate is
effective for preventing hematological changes commonly seen in this
type of leukemias.
Folic acid is a cofactor of thymidilate synthetase during the synthesis of
DNA (1), and it plays an important role in cell division through its action (2)
in the DNA synthesis. Its requirement increases in malignant neoplasms and
leukemias, because cell division is accelerated in such diseases (3). The fact
that a folic acid antagonist, amethopterin (methotrexate, MTX) is effective
for some leukemias and choriocarcinoma (4) suggests that folic acid metabo-
lism is accelerated in these diseases.
Prolongation of the survival time in the animals with leukemias by MTX
has been reported (5) (6). But folic acid metabolism in experimental leukemias
of mice is little known except a report of silverman et al. (7) ; and SoTOBAYASHI
(8) who studied folic acid metabolism in Walker sarcoma.
In the present paper, folic acid metabolism and effects of MTX are
examined in Rauscher leukemic mice to study the relationship between folate
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metabolism and malignant neoplasms.
MATERIALS AND METHODS
1) Mice and preparation of standard virus:
Mature BALB/c mice, weighing 19-25 g and maintained in this laboratory,
were inoculated with Rauscher virus. The virus was obtained from Dr. FRANK
J. R-AUSCHER, National Cancer Institute, Bethesda, Maryland and has been
maintained in this laboratory.
Preparation of virus suspension was as follows; spleens with Rauscher
leukemia were homogenized in a chilled mortar and suspended to 10% by
weight in 0.5 M sodium citrate. This suspension was centrifuged at 1800 x g for
20 min and the supernatant was recentrifuged at 5000 x g for 20 min.
2) Virus inoculum:
A frozen aliquot of concentrated virus was diluted with an equal amount
of sterile 0.9% saline, and 0.2 ml of the diluted virus perparation was inocu-
lated into mice intraperitoneally.
3) Folate assay of plasma, whole blood, liver and spleen:
Blood was taken by heart puncture three to four weeks after virus inocula-
tion. The microbiological assay was made using Lactobacillus casei as test
organism. The method for assaying plasma and whole blood were based on
HARPER et al. (9) and HOFFBRAND et al. (10) respectivelly. Extraction of folic acid
from the liver and spleen was as follows. Five hundred mg of the liver or
spleen tissue was homogenized by adding 10 ml of O. 1 M phosphate buffer (pH
6.0 and 150 mg/dl ascorbic acid added). The spleen of the normal mice was
homogenized as a whole because its weight was below 200 mg. The homo.
genates were autoc1aved for 15 min at 121 ~C and centrifuged at 2000 x g. Free
folate was assayed after diluting the supernatant adequately by the method of
WATERS and MOLLIN (11). The supernatant for assaying total folate was in·
cubated at 37~C for 24 hr after the addition of one ml conjugase solution
(3mg/ml dessicated chicken pancreas" Difco") per 10 ml of the supernatant.
One drop of toluene was poured onto it to avoid the contamination by micro-
organism. Total folate from the conjugase-treated supernatant was assayed
by the same method as that described in the case with free folate. Folic acid
content of the conjugase after incubation for 24 hI' was assayed. Its mean value
was about 400 ng 'g and this amount was negligible because folic acid contents
in the liver and spleen were much greater.
4) Folic acid tolerance test:
Pteroylglutamic acid (40 ,ug/kg) was injected into the mice from the tail
vein. Folate levels in plasma obtained at 15, 30 and 60 min after injecting folic
acid were estimated microbiologically with four leukemic mice and five con.
troIs.
5) Effect of MTX during the development of Rauscher leukemia:
The virus was innoculated into 18 mice. MTX (2mg/kg) was injected into
9 mice intraperitoneally twice a week after five days of the innoculation of the
virus for four weeks. To the remaining 9 mice, 0.5 ml physiologic saline was
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injected as controls. Peripheral blood obtained by incising the tail of mice was
examined before and two, three and four weeks after first injection of MTX.
Bleeding from the wound was' not marked. The examination included red
blood cells, nucleated cells, reticulocytes, hematocrit and differentials of white
blood cells.
RESULTS
1. Folic a~id contents in plasma, whole blood, liver and spleen (Table 1):
TABLE 1 FOLIC ACID CONTENTS OF BLOOD AND TISSUES OF RAUSCHER LEUKEMIC MICE
Plasma* Whole blood* Liver**Free Total
Spleen**
Free Total
Rauscher mice
Normal mice
38.7±13.3
(19)
58. 2± 18. 7
(23)
651. 1± 346.°(19)
488. 8±262. 8
(20)
5. 8±2. 3 11. 4±4. 8 1. 30±0. 49 4.40± 1. 30
(23) (21) (23) (8)
8.2±3.2 16.9±6.50.91±0.24 3.40±1.20
(31) (25) (23) (6)
p value <0.001 N.S. <0.01 <0.01 <0.01 N.S.
* ng/ml ** pg/g
All values are expressed as means ± S. D.. In parenthesis, total number of the mice is
shown.
Significantly low levels of plasma folate was observed in Rauscher leuke-
mia (RL) compared to the control. As shown in Table 2 anemia, reticulocy-
tosis and increase of nucleated cells were prominent at the stage of the
examination (3-4 weeks after virus innoculation). Difference in the folate
levels in whole blood was not significant in both groups. Folic acid contents
in the liver with RL were lower than those of the control in both free and
total folates. Free folic acid content in the spleen with RL was increased
significantly though total folate level did not show any significant increase.
2. Folic acid tolerance test (Fig. 1):
Plasma folate levels reached its peak after 15 min in both groups. The
peak levels in the controls Cl.nd RL were 138 and 72 ngjml, respectivelly, this
difference being significant. In RL, folic acid level showed significantly
lower levels than the control even 30 and 60 min after injecting folate.
3. T he ~ffect of MTX (Table 2) :
No significant changes of the body weight were seen in both groups.
Though red blood cells and hematocrit were decreased as the disease pro-
gressed, degree of the decrease was more marked in non-treated group than
treated group. In the third and fourth weeks of RL virus inoculation, in-
crease of reticulocytes was prevented by givin.g MTX. In MTX·treated
group, the increase of nucleated cells in the peripheral blood was also pre-
vented. The effect of MTX was prominent at the third and fourth weeks of
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Fig. 1 Folic acid clearance test. Horizontal lines and dots indicate means and
S. D., respectivelly. Student-t test revealed that folic acid levels were significantly
low in Rauscher leukemic mice.
TABLE 2 EFFECTS OF METHOTREXATE ON RAUSCHER LEUKEMIA
Before 2 Week 3 Week 4 Week
Body Weight M 23.7±2.9 25.0±2.8 26.2±2.9 26.0±2.6
(g) C 23.6±2.7 25.8±2.9 25.8±2.9 27.8±2.9
Red Blood Cells M 1134. 6± 126.6 983. 9± 75. 3 784.3 ± 89.0*** 656. 4± 123.3**
(x 104/mm3 ) C 1075. 4± 108. 6 964.0±153.4 593.1 ±69. 4 505. 6± 111. 6
Hematocrit M 51.0±1.3 48.3±3.3 41.4±4.2*** 38.9 ± 6.4***
(%) C 48.1 ± 1. 7 44.7±6.3 32.7±1.4 25.1 ±4.l
Reticulocytes M 19.7±7.6 22.7±8.9 76.4±25.2* 110.0±42.0**
(%0) C l8.3±10.2 43.0±28.l l39.0±56.2 l83.2±52.8
Nucleated Cells M 9306±3295** 7156±2746 20828 ± 4154* 26300±8420***
Umm3 ) C 4694± 1413 9078±4ll7 49506± 32804 54913 ± 17975
Erythroblasts M O.22±0.7 1. 11±1.5 4.33±2.9** 8.40±5.8***
(%) C
°
2.33±2.4 11.44±5.8 35.40±12.l
M : Methotrexate treated group (9 mice) C: Control group (9 mice)
* p<O.05 ** p<O.Ol *** p<O.OOl
All values are expressed as means ± S. D.
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DISCUSSION
Low serum folate levels in leukemic patients have been well documented
in the literature (12, 13, 14, 15). Folic acid deficiency has also been reported
in patients with malignant neoplasms (16, 17, 18) and myeloproliferative
syndromes (3). Low folate levels in the plasma and the liver revealed in the
present study suggest that folic acid deficiency is also present in RL of mice.
The clearance test of folic acid showed that disappearance of folic acid from
plasma is rapid in RL. This fact coincides well with the observations made
in human leukemias and indicates that folic acid metabolism is accelerated in
RL. Unexpectedly, an increase of folate in the blood and spleen was ob-
served. This fact rather contradicts the deduction that folic acid deficiency
was present in RL. Further study as to what kinds of folic acid derivatives
increase in these organs will be needed in order to confirm the above pheno-
mena. As shown in Table 2, the increase of reticulocytes and erythroblasts in
the blood was prominent at the third and fourth weeks of RL. According to
the previous histological studies of DUNN et ale (19), YOKORO et ale (20) and
IRINO (21), infiltration of erythroblasts in the spleen was also striking at this
stage. It is well proved that folic acid contents in immature cells such as
reticulocytes and leukemic cells are greater than those in mature cells (22, 23,
24, 25). Therefore, the increase of folic acid in the blood and spleen can be
explained by the increase of immature cells in these organs with RL. Then
a question arises why folic acid did not increase in the liver. According to
the histological studies (19, 20, 21), infiltration of erythroblasts in the liver
appeared a week or more after the erythroblastic foci appeared in the spleen.
Therefore at 3-4 weeks after virus innoculation, erythroblastic proliferation
in the liver was not so extreme as in the spleen. Above all, folic acid con-
tent of the liver is about ten times greater than that of the spleen as seen in
Table 1. Therefore the total folate content of the liver may be decreased
by accelerated metabolism of folate in spite of rather a small increase of
folate by the infiltration of immature cells.
MTX is a strong inhibitor of dihydrofolate reductase (26). The enzyme
plays a very important role in the biosynthesis of DNA. In RL, as accelera-
ted metabolism of folate is probably due to enhanced biosynthesis of DNA,
effect of MTX is expected. The present study revealed that MTX prevents
a progress of the leukemia at the third and fourth weeks. The effect of
MTX on the survival time of RL was studied by CHIRIGOS et al. (27). They
indicated that approximately two·fold or greater increase in the median sur·
vival time over untreated controls (72 days) were obtained with O. 36 mg/kg
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MTX for five days initiated 17 days after the inoculation of the virus. They
also suggested that prolongation of survival time was achieved by MTX
only after the manifestation of RL and not at an early stage of RL. As MTX
can hinder tumor growth by disturbing the biosynthesis of DNA through the
deficiency of tetrahydrofolate, MTX seems to be most effective during the
period when cell division occurs markedly, i. e. at the advanced stage of RL.
As shown in Table 2, progress of anemia is very rapid in the untreated
Rauscher mice. Reticulocytosis was also marked. So a question arises
whether this anemia is a manifestation of leukemia or that of hemolytic ane-
mia. According to the pathological studies of DUNN et at. (19), YOKORO (20)
and IRINO (21), infiltration of immature cells in the spleen and the liver indi-
cates that Rauscher disease has a nature of neoplasm. But very rapid progress
of anemia cannot be explained only by the infiltration of tumor cells to the
hematopoietic organs. Hemolytic process including ineffective erythropoiesis
should also be considered. MTX may be effective for the prevention of ane-
mia by reducing the production of immature cells which are susceptible to
destruction.
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